FAM
CLDX icon

Fred Alger Management’s Celldex Therapeutics CLDX Stock Holding History

Fred Alger Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$585K Buy
+18,454
New +$503K ﹤0.01% 376
2023
Q3 		– Sell
-165,317
Closed -$5.61M – 478
2023
Q2 		$5.61M Sell
165,317
-198,956
-55% -$6.71M 0.03% 240
2023
Q1 		$13.1M Sell
364,273
-156,599
-30% -$6.76M 0.07% 179
2022
Q4 		$23.2M Buy
520,872
+77,230
+17% +$2.76M 0.13% 154
2022
Q3 		$12.5M Buy
443,642
+200,259
+82% +$6.14M 0.06% 190
2022
Q2 		$6.56M Buy
243,383
+87,579
+56% +$2.54M 0.03% 239
2022
Q1 		$5.31M Sell
155,804
-346,321
-69% -$11.1M 0.02% 266
2021
Q4 		$19.4M Sell
502,125
-23,742
-5% -$1.03M 0.05% 209
2021
Q3 		$28.4M Buy
+525,867
New +$24.7M 0.07% 189
2016
Q4 		– Sell
-4,000
Closed -$242K – 491
2016
Q3 		$242K Buy
4,000
+453
+13% +$28.2K ﹤0.01% 371
2016
Q2 		$234K Sell
3,547
-12,796
-78% -$812K ﹤0.01% 409
2016
Q1 		$927K Sell
16,343
-6,362
-28% -$716K ﹤0.01% 382
2015
Q4 		$5.34M Sell
22,705
-2,375
-9% -$518K 0.03% 242
2015
Q3 		$3.96M Sell
25,080
-11,626
-32% -$3.29M 0.02% 294
2015
Q2 		$13.9M Sell
36,706
-369
-1% -$147K 0.06% 188
2015
Q1 		$15.5M Sell
37,075
-15,374
-29% -$5.5M 0.07% 209
2014
Q4 		$14.4M Buy
52,449
+7,411
+16% +$1.84M 0.07% 214
2014
Q3 		$8.76M Sell
45,038
-2,186
-5% -$476K 0.04% 279
2014
Q2 		$11.6M Sell
47,224
-1,440
-3% -$325K 0.06% 263
2014
Q1 		$12.9M Sell
48,664
-21,997
-31% -$8.42M 0.06% 274
2013
Q4 		$25.7M Buy
70,661
+46,984
+198% +$18.1M 0.13% 175
2013
Q3 		$12.6M Buy
+23,677
New +$8.12M 0.07% 269

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Fred Alger Management's CLDX Position: Q1 2026 in Review

Fred Alger Management opened a new position in Celldex Therapeutics (CLDX) in Q1 2026: 18,454 shares worth $585K. The stake represents ﹤0.01% of the portfolio and ranks #376 among its holdings. This is a return to the name: Fred Alger Management previously reported a position in CLDX as recently as Q2 2023.

Fred Alger Management first reported a position in CLDX in Q3 2013 and has held it in 22 quarters since. The position peaked at $28.4M in Q3 2021. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.

  • Fred Alger Management held 18,454 shares of Celldex Therapeutics worth $585K as of Q1 2026.
  • Celldex Therapeutics was a new Fred Alger Management position in Q1 2026.
  • Celldex Therapeutics made up ﹤0.01% of Fred Alger Management's portfolio in Q1 2026, its #376 holding.
  • Fred Alger Management first reported a position in Celldex Therapeutics in Q3 2013 and has held it in 22 quarters since.
  • Fred Alger Management's Celldex Therapeutics position peaked at $28.4M in Q3 2021.
  • 228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.

Based on Fred Alger Management's 13F filing for Q1 2026, filed 15 May 2026.